Delivery Order SPE2DB22D9112-SPE2DB25FTKLA
- Not listed
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $49,324.08, is for the supply of STELARA 90 MG/ML SYRINGEML, a specialized pharmaceutical product. The contract is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program. This IDC enables the DLA to issue...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $49,324.08, is for the delivery of STELARA 90 MG/ML SYRINGEML, a specialized pharmaceutical product. The contract is not associated with any set-aside designation, allowing DMS Pharmaceutical Group to leverage its status as a woman-owned small business to secure this direct federal award....
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $7,538.62 award is for the supply of STELARA 90 MG/ML SYRINGEML, a specialized pharmaceutical product, to support the medical needs of the Department of Defense (DoD). This delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract is valued at $32,882.72 and covers the delivery of STELARA 90 MG/ML SYRINGEML, a specialized pharmaceutical product, to support the medical supply needs of military healthcare facilities. The contract is not associated with any set-aside designation. However, DMS Pharmaceutical Group Inc. holds a...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $49,324.08 contract is for the supply of STELARA 90 MG/ML SYRINGEML, a specialized pharmaceutical product. The delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) between DMS Pharmaceutical Group and the DLA, which enables the agency to issue firm fixed-price orders for a...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $8,220.68, is for the delivery of STELARA 90 MG/ML SYRINGEML, a specialized pharmaceutical product. The contract is not associated with a set-aside designation, allowing DMS Pharmaceutical Group to leverage its status as a woman-owned small business to secure this direct federal award....
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $16,441.36 contract is for the delivery of STELARA 90 MG/ML SYRINGEML, a specialized pharmaceutical product, with a performance period ending on April 22, 2025. DMS Pharmaceutical Group Inc. holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $49,324.08 firm fixed-price contract is for the supply of STELARA 90 MG/ML SYRINGEML, a specialized pharmaceutical product. The award is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program. This IDC enables the DLA to...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract has a ceiling value of $32,882.72 and an ultimate completion date of April 8, 2025. The contract is for the delivery of STELARA 90 MG/ML SYRINGEML, a specialized pharmaceutical product, to support the medical supply needs of military healthcare facilities. DMS Pharmaceutical...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The $49,324.08 contract is for the delivery of STELARA 90 MG/ML SYRINGEML, a specialized pharmaceutical product, with a period of performance through April 3, 2025. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the DLA to...
- SPE2DB22D9112Indefinite Delivery Contract
- SPE2DB22D9112-SPE2DB25FTKLADelivery Order
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $57,544.76, is for the delivery of STELARA 90 MG/ML SYRINGEML, a specialized pharmaceutical product. The contract is part of a larger Indefinite Delivery Contract (IDC) with DMS Pharmaceutical Group Inc., valued at $499,999,999, which allows the DLA to issue delivery orders for a comprehensive range of pharmaceutical items to support the medical supply needs of military health facilities worldwide. This IDC contract covers a diverse portfolio of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, positioning DMS Pharmaceutical Group as a critical supplier in the federal pharmaceutical supply chain. The contract does not have a set-aside designation, allowing DMS Pharmaceutical Group to leverage its status as a woman-owned small business to secure direct federal awards across multiple product categories and medical domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $57.5k | 3/24/25 |